Evaluation of Delcath Systems' Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion

Cardiovasc Intervent Radiol. 2014 Jun;37(3):763-9. doi: 10.1007/s00270-013-0826-5. Epub 2014 Jan 9.

Abstract

Purpose: A new melphalan hemoperfusion filter (GEN 2) was evaluated in a simulated-use porcine model of percutaneous hepatic perfusion (PHP). The current study evaluated melphalan filtration efficiency, the transfilter pressure gradient, and the removal of specific blood products.

Materials and methods: A porcine PHP procedure using the GEN 2 filter was performed under Good Laboratory Practice conditions to model the 60-min clinical PHP procedure.

Results: The mean filter efficiency for removing melphalan in six filters was 99.0 ± 0.4 %. The transfilter pressure gradient across the filter averaged 20.9 mmHg for the 60-min procedure. Many blood components, including albumin and platelets, decreased on average from 3.55 to 2.02 g/dL and from 342 to 177 × 10.e3/μL, respectively, during the procedure.

Conclusion: The increased melphalan extraction efficiency of the new filter is expected to decrease systemic melphalan exposure. In addition, the low transfilter pressure gradient resulted in low resistance to blood flow in the GEN 2 filter, and the changes to blood components are expected to be clinically manageable.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Chemical Analysis
  • Chemotherapy, Cancer, Regional Perfusion / methods
  • Contrast Media / administration & dosage
  • Fluoroscopy
  • Hemofiltration / instrumentation*
  • Liver Circulation*
  • Liver Neoplasms / drug therapy
  • Melphalan / administration & dosage*
  • Melphalan / pharmacokinetics*
  • Models, Animal
  • Swine

Substances

  • Contrast Media
  • Melphalan